Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Atara Shares Fall After Update On Multiple Sclerosis Trial
$Atara Biotherapeutics(ATRA.US)$completed the planned Interim Analysis of the ATA188 Phase 2 study (EMBOLD) in progressive multiple sclerosis patients.
The analysis' primary focus was on expanded disability status scale (EDSS) improvement at six months and overall safety.
The safety monitoring committee believes the six-month interim endpoint may be an inaccurate measure. It recommended continuing the study without sample size adjustment until the final analysis.
The final read-out is planned for October 2023.
Login or create a forever free account to read this news
Sign up/Log in
